Zepbound is an injectable prescription medicine used for chronic weight management in adults. It is indicated for those with a body mass index (BMI) of at least 30 kg/m^2 or at least 27 kg/m^2 with at least one weight-related comorbid condition, and it should be administered alongside a reduced-calorie diet and increased physical activity. Zepbound, known by its generic name tirzepatide, targets both the GLP-1 and GIP hormones and has shown up to 21% weight loss in clinical trials. Common side effects reported include nausea, diarrhea, and vomiting.
In the competitive landscape of weight loss medications, Zepbound will primarily compete with Novo Nordisk’s Wegovy, which is a similar weight loss medication. The U.S. Food and Drug Administration (FDA) has also approved tirzepatide for treating obesity, and it is sold under the brand name Mounjaro when used as a diabetes medication, manufactured by Eli Lilly and Co.
Regarding cost, Zepbound is priced 20% less than its main competitor Wegovy for those with insurance coverage, though the cost remains high at over £500 for a month’s supply. Eli Lilly has announced a discount program for those whose insurance does not cover anti-obesity treatments, offering a 50% discount to these patients.